drugset / Trial / NCT05723874
A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
NaCrossoverOpen-labelTreatment
Summary
The main objective of this trial is to investigate the relative bioavailability of BI 425809 given alone (Reference) compared to a combined administration with the moderate CYP3A4 inducer bosentan (Test) following repeated oral administration.
Timeline
- Start
- 2023-03-06
- Primary completion
- 2023-05-26
- Completion
- 2023-05-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosentan | Other / unclassified | 125 mg | Oral |
| Subject | Iclepertin | Small molecule | 10 mg | Oral |
Indications
No indication recorded.